Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Authors
Ljungman, PMikulska, M
de la Camara, R
Basak, GW
Chabannon, C
Corbacioglu, S
Duarte, R
Dolstra, H
Lankester, AC
Mohty, M
Montoto, S
Murray, John
de Latour, RP
Snowden, JA
Yakoub-Agha, I
Verhoeven, B
Kroger, N
Styczynski, J
Affiliation
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se.Issue Date
2020
Metadata
Show full item recordAbstract
The original HTML and PDF versions of this article were updated shortly after publication to correct author Bregje Verhoeven's name and affiliation. Bregje Verhoeven was incorrectly associated with Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. The correct affiliation is Foundation Hematon, Utrecht, The Netherlands. This has now been corrected in both the PDF and HTML versions of the article.Citation
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020.Journal
Bone Marrow TransplantationDOI
10.1038/s41409-020-0965-7PubMed ID
32514158Additional Links
https://dx.doi.org/10.1038/s41409-020-0965-7Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41409-020-0965-7